Interferons in dermatology. Present-day standard.
Since the first clinical trials in the early 1980s with recombinant interferon, it was possible to show for a variety of indications that cytokines, especially interferons, at certain doses and at respective intervals, when applied in combination with other pharmaceutical compounds open new powerful therapeutic possibilities. Worldwide, recombinant interferon is licensed, especially in dermato-oncology, for the indication of HIV-associated Kaposi's sarcoma, cutaneous T-cell lymphoma, and recently for adjuvant therapy of high-risk malignant melanoma. Recombinant interferon is at present not licensed for dermatologic indication (septic granulomatosis). At the end of our century the indication spectrum for interferons as monotherapy and as combination therapy will undoubtedly be extended. Larger and controlled studies will prove the importance of interferons in dermato-oncology as well as in inflammatory and infectious dermatoses. The combination of interferons with standard therapies will surely be of the utmost importance in dermatotherapy.
Stadler
R
R
Department of Dermatology, Medical Centre Minden, Germany.
D002986:Clinical Trials as Topic; D003880:Dermatology / Q000379:methods; D006801:Humans; D007372:Interferons / Q000009:adverse effects / Q000627:therapeutic use*; D012514:Sarcoma, Kaposi / Q000628:therapy; D012871:Skin Diseases / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D017193:Skin Diseases, Viral / Q000175:diagnosis / Q000628:therapy; D012878:Skin Neoplasms / Q000628:therapy; D016896:Treatment Outcome
D007372:Interferons